Tumor Lysis Syndrome in Primitive Neuroectodermal Tumor
Tumor lysis syndrome (TLS) consists of a triad of hyperuricemia, hyperphosphatemia, and hyperkalemia along with secondary hypocalcemia. It results from the massive release of intracellular ions from chemosensitive tumor cell death. Hematological malignancies such as acute leukemia and non- Hodgkin lymphoma are considered high risk for developing TLS. Solid tumors are considered less likely to develop TLS. We herein report a case of primitive neuroectodermal tumor developing TLS within 24 h of starting chemotherapy. The child developed severe clinical TLS and could not be saved. We think solid tumors with large tumor load needs to be classified as high risk for development of TLS. Prophylactic use of hyperhydration and other medical measures to prevent TLS is warranted in such cases.